Abstract
Hürthle cell carcinomas behave as the most aggressive variant of differentiated thyroid carcinoma of follicular origin, with frequent recurrences and higher morbidity. Its differential diagnosis with Hürthle cell adenoma remains a problem for the clinician and for the pathologist. The vertebrate lectins, galectin-1 and galectin-3 have been implicated in the regulation of cellular growth, differentiation, and malignant transformation in thyroid neoplasms. Galectin-3, a β-galactoside binding protein, has been recently found to be highly expressed in papillary and follicular carcinomas. The current study was undertaken to investigate immunohistochemical reactivity for galectin-3 of thyroid specimen tissues with Hürthle cell adenomas (n=14) and carcinomas (n=17), follicular (n=14) and papillary (n=11) carcinomas, colloid goiter (n=30), Hashimoto’s thyroiditis (n=11), follicular adenoma (n=9), and normal thyroid tissues (n=18). Follicular (78.5%) and papillary (82.0%) carcinomas were frequently reactive for galectin-3, more often when some Hürthle cells were present. There was no galectin-3 immunostaining in any of the specimens from Hashimoto’s thyroiditis, colloid goiters or normal thyroid samples, whereas only one case of follicular adenoma was found positive (11.1%). By contrast, galectin-3 immunostaining in Hürthle cell carcinomas was significantly higher (59%) than in Hürthle cell adenomas (7.1%, p<0.05). These results suggest that galectin-3 may potentially serve as a marker in difficult differential diagnosis cases involving Hürthle cell adenomas and Hürthle cell carcinomas.
Similar content being viewed by others
References
AACE Clinical practice guidelines for the diagnosis and management of thyroid nodules. Endocr Pract 2:78–84, 1996.
Maximo V, Sobrinho-Simões M. Hürthle cell tumours of the thyroid. A review with emphasis on mitochondrial abnormalities with clinical relevance. Virchows Arch 437:107–115, 2000.
Gundry SR, Burney RE, Thpmpson NW, Lloyd R. Total thyroidectomy for Hürthle cell neoplasms of the thyroid. Arch Surg 118:529–532, 1983.
Mc Donald MP, Sanders LE, Silverman ML, Chan HS, Buyske J. Hürthle cell carcinoma of the thyroid gland: Prognostic factors and results of surgical treatment. Surgery 120:1000–1005, 1996.
Bisi H, Camargo RYA, Longatto-Filho A. Role of fine-needle aspiration cytology in the management of thyroid nodules. Diagn Cytopathol 8:504–510, 1992.
Van den Brule FA, Fernandez PL, Buicu C, et al. Differential expression of galectin-1 and galectin-3 during first trimester human embryogenesis. Dev Dyn 209(4):399–405, 1997.
Barondes SH, Cooper DNW, Gitt MA, Leffler H. Galectins: Structure and function of a large family of animal lectins. J Biol Chem 269:20807–20810, 1994.
Moutsatsos IK, Wade M, Schindler M, Wang JL. Endogenous lectins from cultured cells: nuclear localization of carbohydrate-binding protein 35 in proliferating 3T3 fibroblasts. Proc Natl Acad Sci USA 84:6452–6456, 1987.
Inohara H, Akahanli S, Koths K, Raz A. Interactions between galectin-3 and Mac-2-binding protein mediate cell-cell adhesion. Cancer Res 55:3267–3271, 1995.
Liu FT. S-type mammalian lectins in allergic inflammation. Immunol Today 14:486–490, 1993.
Frigeri LG, Zuberi RI, Liu FT. IgEBP, aβ galacto-side-binding animal lectin recognize IgE receptor and activates mast cells. Biochemistry 32:7644–7649, 1993.
Yang RY, Hsu DK, Liu, FT. Expression of galectin-3 modulates T-cell growth and apoptosis. Proc Natl Acad Sci USA 93:6737–6742, 1996.
Inohara H, Honjo Y, Yoshii T, et al. Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms. Cancer 85:2475–2484, 1999.
Raz A, Zhu D, Hogan V, Shah N, Raz T, Karkash R, et al. Evidence for the role of 34 Kda galactoside-binding lectin in transformation and metastasis. Int J Cancer 6:871–877, 1990.
Xu XC, Ni-Naggar AK, Lotan R. Differential expression of galectin-1 and galectin-3 in thyroid tumours: potential diagnostic implications. Am J Pathol 147:815–822, 1995.
Sabattini E, Bisgaard K, Ascani S, et al. The En Vision++ system: a new immunohistochemical method for diagnostics and research. Critical comparison with the APAAP, ChemMate, CSA, LABC, and SABC techniques. J Clin Pathol 51:506–511, 1998.
Orlandi F, Saggiorato E, Pivano G, et al. Galectin-3 is a presurgical marker of human thyroid carcinoma. Cancer Res 58:3015–3020, 1998.
Gasbarri A, Martegani MP, Del Prete F, Lucante T, Natali PG, Bartolazzi A. Galectin-3 and CD44V6 isoforms in the preoperative evaluation of thyroid nodules. J Clin Oncol 17(11):3494–3502, 1999.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Nascimento, M.C.P.A., Bisi, H., Alves, V.A.F. et al. Differential reactivity for galectin-3 in Hürthle cell adenomas and carcinomas. Endocr Pathol 12, 275–279 (2001). https://doi.org/10.1385/EP:12:3:275
Issue Date:
DOI: https://doi.org/10.1385/EP:12:3:275